Ascendis Pharma A/S
ASND
$190.91
-$5.07-2.59%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 534.58M | 393.95M | 391.82M | 354.67M | 343.38M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 534.58M | 393.95M | 391.82M | 354.67M | 343.38M |
| Cost of Revenue | 81.39M | 58.04M | 47.82M | 53.82M | 49.55M |
| Gross Profit | 453.19M | 335.92M | 344.00M | 300.86M | 293.83M |
| SG&A Expenses | 390.69M | 348.60M | 314.76M | 298.13M | 290.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 810.29M | 753.00M | 694.54M | 697.23M | 725.86M |
| Operating Income | -275.71M | -359.04M | -302.73M | -342.55M | -382.49M |
| Income Before Tax | -285.98M | -363.73M | -404.79M | -452.24M | -520.17M |
| Income Tax Expenses | 7.76M | 3.64M | 5.25M | 10.32M | 9.90M |
| Earnings from Continuing Operations | -293.74 | -367.37 | -410.04 | -462.57 | -530.08 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -293.74M | -367.37M | -410.04M | -462.57M | -530.08M |
| EBIT | -275.71M | -359.04M | -302.73M | -342.55M | -382.49M |
| EBITDA | -259.92M | -343.42M | -287.02M | -326.40M | -365.98M |
| EPS Basic | -4.97 | -6.29 | -7.14 | -8.10 | -9.35 |
| Normalized Basic EPS | -3.03 | -3.89 | -4.40 | -4.95 | -5.73 |
| EPS Diluted | -4.97 | -6.29 | -7.14 | -8.10 | -9.35 |
| Normalized Diluted EPS | -3.00 | -3.82 | -4.33 | -4.88 | -5.66 |
| Average Basic Shares Outstanding | 237.79M | 234.68M | 231.55M | 228.32M | 227.06M |
| Average Diluted Shares Outstanding | 241.25M | 238.14M | 235.01M | 231.78M | 230.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |